Fax: (443) 287-2044.
Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review
Version of Record online: 15 NOV 2007
Copyright © 2007 American Cancer Society
Volume 112, Issue 2, pages 228–242, 15 January 2008
How to Cite
Ford, J. G., Howerton, M. W., Lai, G. Y., Gary, T. L., Bolen, S., Gibbons, M. C., Tilburt, J., Baffi, C., Tanpitukpongse, T. P., Wilson, R. F., Powe, N. R. and Bass, E. B. (2008), Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review. Cancer, 112: 228–242. doi: 10.1002/cncr.23157
- Issue online: 4 JAN 2008
- Version of Record online: 15 NOV 2007
- Manuscript Accepted: 9 AUG 2007
- Manuscript Revised: 28 JUL 2007
- Manuscript Received: 22 DEC 2006
- Agency for Healthcare Research and Quality. Grant Number: 290-02-0018
- National Cancer Institute
- National Institutes of Health
- clinical trials;
- underrepresented populations;
- systematic review;
- racial/ethnic minority populations;
- health disparities
Racial and ethnic minorities, older adults, rural residents, and individuals of low socioeconomic status are underrepresented among participants in cancer-related trials. The authors conducted a systematic review to determine the barriers to participation of underrepresented populations in cancer-related trials. Their search included English-language publications that reported original data on the recruitment of underrepresented groups to cancer treatment or prevention trials between 1966 and December 2005 in multiple electronic databases. They also hand-searched titles in 34 journals from January 2003 to December 2005 and they examined reference lists for eligible articles. Titles and abstracts were reviewed to identify relevant studies. Data on barriers to participation were synthesized both qualitatively and based on statistically significant associations with trial enrollment. Of 5257 studies that were cited, 65 studies were eligible for inclusion in the current analysis, including 46 studies on recruitment into cancer therapeutic trials, 15 studies on recruitment into prevention trials, and 4 studies on recruitment into both prevention and treatment trials. Numerous factors were reported as barriers to participation in cancer-related trials. However, only 20 of the studies reported statistically significant associations between hypothesized barriers and enrollment. The available evidence had limitations in quality regarding representativeness, justification of study methods, the reliability and validity of data-collection methods, potential for bias, and data analysis. The results indicated that underrepresented populations face numerous barriers to participation in cancer-related trials. The current systematic review highlighting the literature on recruitment of underrepresented populations to cancer trials and may be used as the evidence base toward developing an agenda for etiologic and intervention research to reduce the disparities in participation in cancer-related trials. Cancer 2008. © 2007 American Cancer Society.
The participation of racial/ethnic minorities and other underrepresented groups in clinical trials is a critical link between scientific innovation and improvements in healthcare delivery and health.1 Since 1993, the National Institutes of Health has required that all sponsored research, including cancer-related trials, ensure the inclusion of women and members of minority groups.2, 3 Between 1993 and 2002, the budget of the National Cancer Institute (NCI) doubled, and clinical trial accrual increased.4 Nevertheless, only 2.5% of cancer patients are enrolled into trials, and the following populations are underrepresented among participants in NCI-funded clinical trials: African-American men, Latinos/Hispanics, Asian and Pacific Islanders, American Indians/Alaska Natives, adolescents, older adults (aged ≥65 years), individuals who reside in rural areas, and individuals of low socioeconomic status.5 Most publications that report the results from cancer clinical trials do not describe the participants' race or ethnicity.6 This lack of diversity in randomized study populations reduces opportunities for discovering effects that may be particularly relevant to underrepresented populations6, 7 and contributes to inequitable distribution of benefits and risks of trial participation.1, 8 Some investigators have suggested that access to clinical trials should be an objective9 and a component of state-of-the-art cancer care.10
Racial differences in access to state-of-the-art care contribute to disparities in cancer mortality and survival after cancer diagnosis.4, 11, 12 However, these disparities disappear when African Americans and Caucasians receive similar cancer treatment for same-stage disease.13 A number of publications have documented key barriers to participation in cancer-related trials; however, there is a lack of systematic review and synthesis of the barriers that affect accrual of underrepresented populations to cancer-related trials. We performed a systematic review of the literature regarding barriers to participation of underrepresented populations in controlled trials of cancer prevention or treatment and investigated whether these barriers vary by sociodemographic factors, cultural factors, or both.
MATERIALS AND METHODS
For this review, “underrepresented populations” included adolescents, older adults (aged ≥65 years), individuals of low socioeconomic status, individuals who resided in rural areas, African Americans, Latinos/Hispanics, Asian Americans and Pacific Islanders, and American Indians/Alaska Natives.
Our previously described conceptual model14 was modified to demonstrate the relations between factors that lead to enrollment in a clinical trial (see Fig. 1). According to this model, to accept or refuse participation in a clinical trial, an individual must be aware that the study is being conducted and must have an opportunity to participate.15 Given the opportunity to participate, an individual may seek additional information, thereby achieving greater awareness of trials and of the potential harms and benefits of participation. The conceptual framework categorizes barriers based on their predicted effects on awareness, opportunity, and the decision about participation.
Inclusion Criteria and Data Abstraction
Our search strategy for relevant articles has been reported elsewhere.15 Briefly, it involved 1) a keyword search of electronic databases from 1966 to December 2005, including the MEDLINE database, the Cochrane Central Register of Controlled Trials (Issue 1, 2003); the Cochrane Database of Methodology Reviews (CDMR); the Cumulative Index of Nursing and Allied Health Literature database (CINAHL); the Psychological Abstracts data base (PsycINFO); and the Campbell Collaboration's Social, Psychological, Educational, and Criminological Trials Register (C2-SPECTR); 2) a hand search of 34 relevant journals from January 2003 through December 2005, which was the end date for eligible publications; 3) an examination of reference lists from eligible articles; and 4) an author search in MEDLINE of selected experts known to have interests related to our questions.
To be included, an article had to be written in English and had to report original data on barriers to participation of underrepresented populations into a cancer prevention or treatment trial. Potential articles from the title and abstract reviews were abstracted fully by using a structured instrument. During the article review phase, data were abstracted twice from 270 articles by using a standardized data abstraction form and a serial article review process (Fig. 2). This involved a primary reviewer, who completed the data abstraction form, and a secondary reviewer, who checked the primary review for accuracy and completeness. Data captured on the abstraction forms included whether specific patient, provider, study design, and healthcare system level barriers were associated with statistically significant or qualitatively important decreases in enrollment to clinical trials. Both reviewers performed an independent assessment of the study's quality by using a separate quality-assessment form. Unresolved disagreements between reviewers were adjudicated by a third reviewer in the group. Data from the article review process were entered into a relational database, ProCite (ISI ResearchSoft, Berkeley, Calif). The database was used to maintain and clean the data and to create evidence tables.
Grading of the Total Body of Evidence
The evidence-grading scheme was based on the approach recommended by the International Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group.16 The evidence was downgraded for limitations in quality, important inconsistencies, imprecise/sparse data, high probability of reporting bias, or uncertainty about how or the extent to which the individuals, measures, and/or outcomes were similar to those of interest.16 Study quality was evaluated based on 5 domains: representativeness, justification of study methods, reliability and validity of data-collection methods, potential for bias, and data analysis. To calculate quality scores for each area or domain, we averaged Reviewer A and Reviewer B scores. A score ≥50% in 1 of the 5 domains was deemed “adequate”; conversely, a score from 0% to 49% in any of the 5 domains was deemed “inadequate.”
Of 5257 citations, 65 eligible articles served as the basis for this analysis (Fig. 2).5, 10, 17–77,83,88 The most frequent reasons for exclusion at abstract review were not reporting a controlled trial or recruitment to a controlled trial and no original data. The most frequent reasons for exclusion at article review were not addressing an underrepresented group and not reporting on a controlled trial. Because of the diversity of target populations and heterogeneity of study designs, a formal quantitative summary of pooled study effects, or meta-analysis, was not possible. However, a qualitative synthesis of the available evidence is provided below.
The study characteristics are summarized in Table 1. Greater than 50% of the 65 articles (n = 41 studies) were published in 2001 or later, 14 were published between 1996 and 2000, and 10 were published in 1995 or earlier. Most of the articles were descriptive/cross-sectional (n = 33 studies). Twenty-four articles used qualitative methods. The articles reported on recruitment in diverse settings, including hospitals (n = 43 studies) and community (n = 35 studies). Studies of accrual to cancer therapeutic trials (n = 45 studies) were more common than those of accrual to prevention trials (n = 15 studies) and chemoprevention trials (n = 4 studies). In most articles (n = 55 studies), the respondents were patients or participants. Nearly 66% of the articles (n = 43 studies) reported on barriers to accrual to an actual trial. The remaining articles (n = 22 studies) reported on barriers in the absence of an actual trial (n = 13 studies). Outcome measures for these studies included respondents' willingness to participate (n = 10 studies) or perceived barriers to participation (n = 13 studies).
|Study/Year||Sample size||Study setting||Target population||Targeted underrepresented population||Study design||How measured||Type of cancer studied||Type of cancer trial into which recruited|
|Adams-Campbell, 200417||235||University medical center||Patients/participants, physicians||AA||Tumor registry review||Enrollment||Breast, colorectal, head and neck, lung, prostate||Treatment|
|Advani, 200318||218||Hospital outpatient||Patients/participants||AA||Case-control||Surveys, phone interview||Solid/hematologic malignancies (excluding melanoma)||Treatment|
|Bailey, 200419||175||University medical center||Patients/participants||AA||Descriptive||Case report||Cervical||Treatment|
|Barofsky and Sugarbaker, 197920||103||Community, hospital inpatient||Patients/participants||AA||Qualitative||Semistructured interview||Histologically confirmed soft tissue or osteosarcoma||Treatment|
|Berman, 199821||435||Community||Patients/participants||Lat/Hisp, AA||Quasiexperimental||Survey, enrollment||Smoking cessation||Prevention|
|Bieniasz, 200322||66||Community||Patients/participants||AA women||Qualitative||Semistructured interview||Cervical (dysplasia)||Prevention|
|Brewster, 200223||545||Community, hospital outpatient||Patients/participants||Lat/Hisp women||CCT||Enrollment||Cervical||Prevention|
|Broome and Richards, 200325||34||Hospital inpatient||Patients/participants||Children, adolescents||Qualitative||Semistructured interview||Ewing sarcoma, hematologic malignancies||Treatment|
|Broome, 200124||34||Community, hospital inpatient, hospital outpatient||Patients/participants||Children, adolescents||Qualitative||Interview||Hematologic malignancies, solid tumors||Treatment|
|Brown, 200026||434||Hospital outpatient||Patients/participants||AA and Hisp women||Descriptive||Survey, interview, enrollment||Breast, cervical||Prevention|
|Brown and Topcu, 200327||438||Community||Patients/participants||AA||Cross-sectional, descriptive||Telephone surveys||NR||Treatment|
|Chen, 200028||68||Hospital inpatient||Patients/participants||Older adults||Hospital registry review, retrospective||Enrollment NR||Aggressive histology lymphoma||Treatment|
|Comis, 200329||887||Community||Patients/participants||Older adults (by subgroup analysis)||Cross-sectional, descriptive||Telephone interview||NR||Treatment|
|Cook, 200530||35,534||Community, other (SWOG)||Patients/participants||AA, Hisp, Asians||Descriptive||Focus groups||Prostate||Prevention|
|Diener-West, 200131||4191||Hospital inpatient, hospital outpatient, group practice, solo practice||Patients/participants||Older adults||RCT||Enrollment, face-to-face interview||Eye||Treatment|
|Ellington, 200632||55||Community||Patients/participants||Hisp||Qualitative||Focus groups||All||Treatment|
|Ford, 200433||12,400||Community||Patients/participants||AA men||RCT||Enrollment NR||Prostate, lung, colorectal||Prevention|
|Fouad, 200034||103||Community||Patients/participants, physicians||AA||Qualitative||Focus groups/key informant interview||NR||NR|
|Fouad, 200183||103||Community||Patients/participants, physicians||AA||Qualitative||Focus groups/key informant interview||NR||NA|
|Fouad, 200488||373,158||Community||Patients/participants||AA, American Indian, Asian/Pacific, Hisp||Descriptive||Survey||All cancers||Prevention|
|Grann, 200535||823||Community||Patients/participants||AA and Hisp women||Descriptive||Survey||Breast||Prevention|
|Green, 200036||103||Community||Patients/participants||AA||Qualitative||Focus group||NR||NR|
|Gross, 200540||8121||NCI Cooperative Group breast cancer trials||Patients/participants||Older adults, low SES, AA||Case-control||NCI CTEP data||Breast||Treatment|
|Gross, 200539||16,135||NCI-sponsored lung, breast, colorectal, prostate cancer trials||Patients/participants||Older adults||Longitudinal analysis||NCI CTEP data||Breast, colorectal, lung, prostate||Treatment|
|Gross, 200537||36,167||NCI-sponsored lung, breast, colorectal, prostate cancer trials||Patients/participants||Older adults||Cross-sectional, descriptive||NCI CTEP data||Breast, colorectal, lung, prostate||Treatment|
|Gross and Krumholz, 200538||1418 Counties||NCI-sponsored lung, breast, colorectal, prostate cancer trials||Patients/participants||Uninsured, rural, low SES||Descriptive, cross-sectional||NCI CTEP data||Breast, colorectal, lung, prostate||Treatment|
|Grunfeld, 200241||29||Hospital inpatient||Researchers||Clinical research associates||Qualitative||Semistructured interview||NR||Treatment|
|Hunter, 198742||17,773||Group practice, hospital inpatient||Patients/participants||AA||Descriptive, qualitative, retrospective||Secondary analysis of program data||All||Treatment|
|Jatoi, 200543||226||NCCTG||Patients/participants||Older adults||Descriptive, retrospective||NCCTG Clinical Trial registry||Nonsmall cell lung cancer||Treatment|
|Kaluzny, 199344||NR||Community, hospital outpatient, group practice||Patients/participants, physicians||NR||Descriptive, qualitative||NCI patient log, interviews from site visits||NR||Treatment|
|Kemeny, 200345||154||Community||Patients/participants, physicians||Older adults||Case-control||Patient interviews, self-administered written questionnaires for physicians||Breast||Treatment|
|Kemp, 198446||1022||Community||Patients/participants||Older adults (by subgroup analysis)||Descriptive, cross-sectional||Face-to-face interview, survey||Breast, bone||Treatment|
|Kimmick, 200547||101 Symposium, 29 seminar, 500 monthly e-mails, 800 monthly mailings||CALGB institutions (community and academic hospitals)||Physicians and healthcare providers||Older adults||RCT||Enrollment||Cancer in general (breast, prostate, leukemia, lymphoma, melanoma, genitourinary)||Treatment|
|Kornblith, 200248||156||Hospital inpatient||Physicians||Older adults||Cross-sectional, descriptive||Questionnaire||Breast||Treatment|
|Krailo, 199349||2788||Hospital inpatient, hospital outpatient||Patients/participants||Children, adolescents||Hospital registry review, qualitative||Enrollment NR||All||Treatment|
|Lara, 200150||276 Patients, 18 physicians||Hospital outpatient clinic||Physicians||Older adults||Descriptive||Survey||All||Treatment|
|Lara, 200551||596||University medical center||Physicians||AA, Asian/Pacific Islander, Hisp||Descriptive||Survey||All||Treatment|
|Lee, 199952||165||Hospital inpatient||Patients/participants||AA men||Descriptive, cross-sectional||Survey||Prostate||Prevention|
|Lerman, 199453||271||Community||Patients/participants||AA women||Descriptive, cross-sectional||Structured telephone interview||Breast||Prevention|
|Lewis, 200354||59,300||NCI cooperative groups||Patients/participants||Older Adults||Cross-sectional, descriptive, retrospective||Secondary analysis of national database (NCI, CTEP, PDQ, SEER)||NR||Treatment|
|Ling, 200055||1206||Hospital inpatient, hospital outpatient||Patients/participants||Older adults (by subgroup analysis)||Qualitative||Survey||NR||Treatment|
|Mandelblatt, 200556||450 (Intervention, n = 232; control, n = 218)||Community health facility||Patients/participants||Hisp/Lat women||RCT||Intent to participate||Breast||Prevention|
|Martel, 200457||23 Providers, 216 patients||University medical center||Patients, physicians||Older adults||Descriptive||Survey||All||Treatment|
|McCaskill-Stevens, 199958||89||Community||Physicians||AA||Qualitative||Workshops with discussions and questionnaires||All||Prevention, treatment|
|Melisko, 200559||297 patients, 127 physicians||Community health facility, hospital outpatient clinic, private and academic medical centers||Patients, physicians||Minorities||Descriptive, cross-sectional||Mailed survey for physicians, face-to-face survey for patients||Breast||Treatment, (Complementary and Alternative Medicine)|
|Millon-Underwood, 199360||220||Community||Patients/participants||AA||Descriptive, cross-sectional||Survey||NR||Prevention, treatment|
|Moinpour, 200061||NR||Hospital outpatient, University medical center||Patients/participants, researchers||AA and Hisp men||RCT||Enrollment NR||Prostate||Prevention|
|Mouton, 199762||80||Community||Patients/participants||AA women||Descriptive, cross-sectional||Telephone survey||Breast, colorectal||Prevention|
|Murthy, 200463||75.215||NCI-sponsored lung, breast, colorectal, prostate cancer trials||Patients/participants||Minorities (AA, Hisp, Asian/Pacific Islanders, American Indian/Alaskan Native), older adults||Cross-sectional, descriptive||Secondary analysis of NCI Cancer Clinical Data Update Service||Breast, colorectal, lung, prostate||Treatment|
|Outlaw, 200010||52||Hospital inpatient||Physicians, data managers||AA||Qualitative||Survey||NR||NR|
|Paskett, 200264||360||Community||Physicians||Rural||CCT||Survey, enrollment NR||Breast, colorectal||Treatment|
|Paterniti, 200565||59 Patients observed||University medical center||Patients/participants, families/caregivers||Asian Americans||Qualitative||Field observation||All||Treatment|
|Pinto, 200066||73||Community||Physicians||AA||Qualitative||Focus groups||NR||Prevention, treatment|
|Randall-David, 200167||37||Community||Patients/participants||Rural||Qualitative||Focus groups||All||Treatment|
|Roberson, 199468||28||Community||Patients/participants||AA, American Indian or Alaskan Native, Lat/Hisp||Qualitative||Telephone survey||NR||Treatment|
|Robinson, 199669||46||Community||Patients/participants||AA men||Qualitative||Focus groups||Prostate||Treatment|
|Sateren, 20025||24,332||All patients from NCI-funded trials between April 1998 and April 1999||Patients/participants||AA||Cross-sectional, descriptive, retrospective||Secondary analysis of national database (US Census, SEER)||All||Treatment|
|Sears, 200370||558||Community||Patients/participants||AA women||RCT, retrospective||Enrollment NR||Breast||Treatment|
|Simon, 200471||319||Hospital inpatient||Patients/participants||AA||Descriptive||Survey||Breast||Treatment|
|Spaight, 198472||23||Hospital inpatient||Physicians||Older adults||Qualitative||Structured interview||NR||Treatment|
|Tercyak, 200673||209||Hospital tumor registry||Patients/participants||Adolescents||Descriptive||Telephone interviews||All||Survivorship|
|Thornquist, 199174||1284||Community||Patients/participants||Older adults (by subgroup analysis)||Cohort, prospective||Enrollment NR||Lung||Prevention|
|Trauth, 200575||299||Community||Patients/participants||AA women||Qualitative||—||Lung, colorectal, ovarian||Prevention|
|Twelves, 199876||4688||Hospital inpatient, hospital outpatient, solo practice||Patients/participants||Older adult women (by subgroup analysis)||Retrospective, tumor registry review||Enrollment NR||Breast||Treatment|
|Woods, 200277||120||Hospital outpatient||Patients/participants||AA||Qualitative||Focus groups/interview||NR||Prevention, treatment|
The majority of the articles (n = 35 studies) reported data on African-American participants; fewer studies focused on Latinos/Hispanics (n = 12 studies), Asian and Pacific Islanders (n = 6 studies), and American Indians/Alaska Natives (n = 4 studies). Whereas some articles reported on the accrual of older adults (n = 19 studies), only 4 articles focused exclusively on adolescents or children. We did not synthesize the evidence on barriers by trial type (eg, Phase I/II vs Phase III trials), because most of the studies did not specify trial phase.
The eligible studies identified 150 distinct barriers to accrual to cancer-related trials, including 124 barriers to accrual to therapeutic trials only, 26 barriers to accrual to prevention trials only, and 32 barriers to accrual to both therapeutic and prevention trials. The studies reported 8 barriers to awareness, 88 barriers to the opportunity to participate, and 44 barriers to acceptance of enrollment into a cancer-related trial. Among these, 79 barriers were relevant at the patient level, 37 were relevant at the provider level, 25 were relevant at the study design level, and 8 were relevant at the healthcare systems level. The most frequently reported barriers were 1) mistrust of research and the medical system (n = 20 studies), 2) perceived harms (n = 18 studies), 3) costs of participating (n = 17 studies), 4) patient demographics (n = 16 studies), 5) availability of transportation (n = 15 studies), 6) lack of education about clinical trials (n = 13 studies), 7) fear (n = 10 studies), 8) time commitment (n = 9 studies), and 9) family issues (n = 8 studies) (see Fig. 3).
Barriers to Awareness, Opportunity, and Acceptance of Enrollment
Barriers to clinical trial awareness
Table 2 lists the factors that were associated with a statistically significant decrease in reported enrolment (Fig. 4). Three articles18, 51, 75 reported an association between lack of awareness and reduced participation in trials. In addition, one of those studies reported lack of knowledge about the origins of cancer as a barrier to enrollment.75 Qualitatively, in the 18 studies that reported on barriers to awareness, lack of education regarding clinical trials was the most frequently reported barrier (n = 13 studies). Additional awareness barriers included lack of culturally appropriate information (n = 6 studies), cancer knowledge (n = 5 studies), and physician awareness of trials (n = 4 studies)
|Author and year||Barriers to enrollment|
|Advani, 200318||Patient barriers: Lack of education about clinical trials||—||Patient barriers: Perceived harms of clinical trial participation; chance of side effects; distance to clinic|
|Bieniasz, 200322||—||—||Patient barrier: Intervention characteristics|
|Brown and Topcu, 200327||—||Patient barriers: African American older age; lower income||—|
|Diener-West, 200131||—||Patient barriers: Age; living near treatment center||—|
|Ford, 200433||—||Patient barriers: Unlisted telephone number; age||—|
|Grann, 200535||—||Patient barriers: SES; African American race||—|
|Gross, 200540||—||Patient Barriers: SES (reside in high poverty zip code)||—|
|Gross, 200539||—||Patient barriers: Poverty; study design barriers: no. of comorbid conditions||—|
|Gross, 200537||—||Study design barriers: Comorbidity exclusion; age exclusion||—|
|Gross and Krumholz, 200538||—||Provider barriers: Index of managed care competition||—|
|Kemeny, 200345||—||Patient barriers: Age; study design barriers: disease stage, no. of comorbidities||—|
|Lara, 200551||Patient barriers: Lack of education about clinical trials||Patient barriers: Race (African American or Asian); age (18–24 y); income < $25,000||—|
|Martel, 200457||—||Provider barriers: Referral source (ie, surgeons)||—|
|Melisko, 200559||—||—||Patient barriers: Transportation; time commitment; loss of income; loss of control|
|Murthy, 200463||—||Patient barriers: Race (African American; Hispanic)||—|
|Sateren, 20025||—||Patient barriers: Lack/inadequate health insurance; being a black man aged 30–59 y; Asian adults and Latino/Hispanic adults||—|
|Simon, 200471||—||Patient barriers: Lack/inadequate health insurance||—|
|Thornquist, 199174||—||Patient barriers: Age (50–54 y; 65–69 y)||—|
|Trauth, 200575||Patient barriers: Lack of knowledge about origins of cancer; lack of education about clinical trials||—||—|
|Twelves, 199876||—||Patient barriers: Age||—|
Barriers to opportunity to participate
Sixteen articles reported an association between lack of opportunity and reduced participation in trials.5, 27, 31, 33, 35, 37–40, 45, 51, 57, 63, 71, 74, 76 Most of those articles reported an association between specific sociodemographic characteristics, such as older age, socioeconomic status, and racial/ethnic minority status, along with lack/inadequate health insurance and reduced enrollment (Table 2). Additional opportunity barriers include study design barriers, namely, comorbid conditions and age-based exclusion,37, 39, 45 lack of provider referral,57 and the extent of managed care competition.38 Qualitatively, the most frequently reported barriers to the opportunity to participate related to provider attitudes (n = 19 studies) and patient eligibility criteria (n = 18 studies); exclusion criteria, such as comorbid conditions (n = 11 studies) and functional status (n = 9 studies); patient/provider communication or the provider's method of presenting information about the trial to the patient (n = 7 studies); and the provider's data-collection costs or burden (n = 6 studies). In some studies, demographic factors, such as age (n = 8 studies), race/ethnicity (n = 6 studies), and not being married (n = 1 study), in themselves, were associated with reduced opportunity to participate (Fig. 5).
Barriers to acceptance of enrollment
Three articles reported an association between specific factors and the decision not to participate in trials (Fig. 6).18, 22, 59 These barriers included the perceived harms of clinical trial participation, loss of control (uncertainty about treatment allocation), the nature of the intervention, the time commitment, loss of income, and transportation. Qualitatively, the most frequently reported barriers to acceptance of participation were mistrust of research and the medical system (n = 20 studies), direct and indirect costs of participation (n = 17 studies), transportation (n = 14 studies), time commitment (n = 10 studies), fear (n = 9 studies), family considerations (n = 8 studies), and factors related to the patient-provider relationship or the perception of the provider (n = 10 studies). Whereas mistrust was the most frequently reported barrier factor in the eligible studies, none of the studies reported a statistically significant association between mistrust and reduced enrollment.
Effects of Demographic Factors
Older age, (n = 13 studies), lower socioeconomic status (n = 8 studies), and racial/ethnic minority status (n = 6 studies), in themselves, were reported as barriers to recruitment. These demographic factors related most frequently to study design barriers, such as exclusion by age restriction (n = 6 studies), comorbid conditions (n = 11 studies), functional status (n = 8 studies), and study duration and/or complexity of study procedures (n = 5 studies). In the recruitment of adolescents, parental influence was reported as a factor that influenced acceptance of participation (n = 4 studies). Across underrepresented populations, it was difficult to separate race/ethnicity and socioeconomic status from the barriers themselves.
Effects of Language and Cultural Factors
Thirteen articles reported that cultural factors, including lack of culturally relevant education about clinical trials (n = 7 studies), particularly in native languages of target populations (n = 6 studies), enhanced communication barriers. However, none of those articles reported on statistically significant associations between these factors and reduced trial enrollment. Moreover, the heterogeneity of the evidence and the overlap among underrepresented populations (eg, older African-American adults) limited our ability to synthesize the evidence regarding whether and how specific barrier factors vary across cultural contexts.
Quality of Studies
We assessed the quality of the 65 studies based on each of 5 criteria: representativeness, justification, bias, reliability and validity, and statistical analysis (Fig. 7). In terms of representativeness, 66% of the articles (n = 39 studies) clearly described the participants and settings. For the justification of study methods, 60% of the articles (n = 39 studies) provided an adequate rationale based on a conceptual model, a statement of the research question and objectives, and an adequate justification of the target population. The survey instruments and data-collection methods used in the majority of studies (n = 56 studies) showed limitations in reliability and validity. Eighteen studies used adequate measures to protect against bias or confounding. Only 8 studies provided adequate information to assess the quality of their data analysis.
The overall quality of the evidence on barriers to participation was assessed as low because of limitations in the quality and precision of eligible articles, lack of strong evidence within the studies, the high probability of reporting bias, and lack of a quantitative estimate of effect size.16 Although the studies were heterogeneous and contained > 627,044 participants in total, lack of information to answer our study questions was most prominent for Latino/Hispanics, American Indians/Alaska Natives, Asian and Pacific Islanders, adolescents, and rural populations.
Our systematic review suggests that numerous factors affect participation of underrepresented populations in cancer-related trials. However, few of the eligible articles reported a statistically significant association between specific barriers and clinical trial enrollment (Table 2). Consistent with our hypothesized conceptual framework, these barriers may influence recruitment outcomes through their effects on awareness of trials, the opportunity to participate, and the decision to accept or refuse participation.
The most commonly reported barrier factors relate to the opportunity to participate in trials; and among opportunity factors, individual characteristics, such as age, socioeconomic status, racial/ethnic minority status, and comorbid conditions, are associated most consistently with reduced clinical trial enrollment. Because opportunity barriers largely reflect protocol design as well as the process of study implementation, investigators play a major role in determining the extent to which trials are accessible to underrepresented groups.78 If such opportunity barriers affect underrepresented groups disproportionately, then they likely contribute to disparities in participation rates. However, taken together, the studies that demonstrate an association between opportunity barriers and reduced enrollment provide limited information about potential mechanisms that lead to the observed disparities in enrollment on the basis of race/ethnicity. Clearly, exclusion criteria based on age and comorbid conditions constitute barriers to enrollment of older adults. Nonetheless, the mechanisms that reduce opportunities for racial/ethnic minority populations are less evident, and they cannot be separated easily from the effects of low socioeconomic status. Our qualitative synthesis of the literature offers a wide array of hypothesized barriers that await confirmation as determinants of reduced opportunity for enrollment for racial/ethnic minority populations. However, until the effects of such barriers to enrollment are assessed quantitatively, uncertainty will persist about the mechanisms of reduced trial enrollment opportunities for racial/ethnic minorities.
Despite these limitations, the eligible articles suggest that there are multiple potential ways to improve opportunities for enrollment of underrepresented populations, including less rigid study designs and developing systems that facilitate the participation of healthcare providers. However, the steps taken by researchers to increase enrollment too often will prove inadequate in the absence of an infrastructure to support trials.80–82 Moreover, given the prominence of inadequate health insurance as a barrier, policy-level interventions are needed urgently to address the costs of trial participation.
Our qualitative synthesis of the literature illuminates multiple hypothesized barriers to awareness, including lack of trial dissemination and targeting of clinical trial enrollment opportunities on the basis of the cultural background and literacy level of the target population. However, only 3 studies demonstrated an association between lack of awareness (specifically, lack of education about clinical trials) and enrollment. On a qualitative basis, several articles suggested culturally targeted education as a strategy for increasing trial participation10, 32, 33, 51, 65, 75, 83; however, none of the eligible articles reported an association between culturally targeted education strategies and trial enrollment. This question needs to be addressed in future studies.
Similarly, many of the eligible articles identified psychosocial and cultural factors in the decisional balance regarding acceptance or refusal of participation in cancer-related trials. However, only 3 articles reported an association between specific factors and refusal to participate in trials. It is noteworthy that, whereas mistrust was the most frequently reported barrier factor in the eligible articles, none of the 20 articles that identified mistrust as a barrier factor reported a statistically significant association between mistrust and reduced enrollment. In this respect, the disconnect between the qualitative data and quantitative findings reflects, in part, the lack of standardized, quantitative measures of trust as applied to studies of determinants of trial enrollment: None of the 20 articles that reported trust as a barrier factor used a quantitative measure of trust.
The available literature suggests the need to improve the quality of studies on the recruitment of underrepresented populations. Among the articles on recruitment to cancer-related trials, as reported recently, we identified few randomized controlled trials or concurrent controlled trials.87 Likewise, in the current article, we report a rich qualitative literature with limited quantitative evidence on barriers to enrollment. There is an urgent need for hypothesis-driven, quantitative studies with enrollment into a trial as the primary outcome variable. Such an approach would help validate observations made in qualitative studies and would facilitate the eventual application of meta-analytic techniques toward identifying the most critical barriers and the most promising intervention strategies.
The available evidence presents limitations in study quality with regard to 1) representativeness, 2) justification of study methods, 3) reliability and validity of data-collection methods, 4) the potential for bias/confounding; and 5) data analysis. Our search strategy included strict eligibility criteria, and some articles that contained potentially relevant evidence were not included in this review.9, 84–86 We used a standardized approach to generate the body of evidence that is presented in this review. However, because of the heterogeneity of study designs, we did not use formal meta-analytic techniques. In addition, many of the articles that were included did not facilitate a distinction between early-phase clinical trials and Phase III clinical trials.
For this review, we combined the results from both prevention and therapeutic trials. In reviewing prevention and treatment trials separately,15 we observed that there were similar barriers of awareness, opportunity, and acceptance for both prevention and therapeutic trials. Although, individually, many of the studies limited our ability to reach firm conclusions, the sum of the evidence and its consistency across multiple studies allow us to construct a conceptual framework for barriers to participation in cancer-related trials (Fig. 8).
In conclusion, the underrepresented populations in cancer-related trials face numerous barriers to participation. The number and complexity of the reported barriers to participation suggest that there is an urgent need for well-designed studies with appropriate methods and measures to establish key determinants of awareness, opportunity, and acceptance of participation. Knowledge of such determinants would provide the basis for the design of evidence-based intervention strategies directed to participants/patients, providers, institutions, and communities. Our systematic review highlights the state of the science on recruitment of underrepresented populations to cancer trials. It summarizes reported determinants of enrollment of underrepresented populations in cancer-related trials. It can be used as the evidence base toward developing an agenda for etiologic and intervention research to reduce the disparities in participation in cancer-related trials. This urgent need should be given a high priority.
This article is based on research conducted by Johns Hopkins Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (contract no. 290-02-0018), Rockville, Md, with funding and scientific support provided by the National Cancer Institute, National Institutes of Health. The authors of this article are responsible for its contents, including any clinical and treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality, the National Cancer Institute, the National Institutes of Health, or of the United States Department of Health and Human Services.
- 1Institute of Medicine. The Unequal Burden of Cancer: An Assessment of NIH Research and Programs for Ethnic Minorities and the Medically Underserved. Washington, DC: National Academy Press; 1999.
- 2National Institute of Health. Monitoring Adherence to the NIH Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research. Available at URL: http://www4.od.nih.gov/orwh/GoldReport_2000-01.pdf Accessed October 1, 2004.
- 3National Institute of Health. NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research—amended October, 2001. Available at URL: http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm Accessed October 1, 2004.
- 14Race and research in focus: perspectives on minority participation. In: BettinaM, ed. Health Studies: Clinical Trials. Washington, DC: American Public Health Association; 2004., .
- 15Evidence Report on Knowledge and Access to Information on Recruitment of Underrepresented Populations to Cancer Clinical Trials. Evidence Report/Technology Assessment No 05-E019-2 ed. Baltimore, Md: Johns Hopkins University Evidence-based Practice Center; 2005., , , et al.
- 20Determinants of patient nonparticipation in randomized clinical trials for the treatment of sarcomas. Cancer Clin Trials. 1979; 2: 237–246., .
- 24Children in research: the experience of ill children and adolescents. J Fam Nurs. 2001; 7: 32–49., , .
- 73Identifying, recruiting, and enrolling adolescent survivors of childhood cancer into a randomized controlled trial of health promotion: preliminary experiences in the Survivor Health and Resilience Education (SHARE) Program. J Pediatr Psychol. 2006; 31: 252–261., , , , .